Upstream Bio's Verekitug Shows 56% Reduction in Asthma Exacerbations in Phase 2 Trial — Upstream Bio, Inc.

Event summary

Verekitug, 100 mg dosed every 12 weeks, reduced annualized asthma exacerbation rate (AAER) by 56% compared to placebo in severe asthma patients.
Phase 2 VALIANT trial enrolled 478 patients, showing statistically significant improvements in lung function (FEV1) and exhaled nitric oxide (FeNO).
Upstream Bio plans to initiate Phase 3 trials for severe asthma and CRSwNP in Q1 2027, evaluating a 400 mg quarterly regimen.
Over 500 trial participants treated with verekitug across clinical development programs, with long-term extension study data expected in H2 2027.

The big picture

Upstream Bio's Phase 2 results for verekitug highlight the potential of TSLP receptor inhibition as a differentiated approach in severe asthma. The company's strategy of targeting multiple inflammatory pathways positions it competitively in a market where existing biologics still leave unmet needs. The planned Phase 3 trials will be critical in determining whether verekitug can achieve best-in-class efficacy with quarterly dosing, a key differentiator in patient convenience.

What we're watching

Clinical Efficacy: How the 56% reduction in AAER will position verekitug against existing severe asthma treatments in Phase 3 trials.
Regulatory Pathway: Whether Upstream Bio can secure approval for the 400 mg quarterly regimen without additional safety concerns.
Market Differentiation: The pace at which verekitug can establish itself as a best-in-class option for severe asthma and CRSwNP.